Adamsbrown Wealth Consultants LLC Has $269,000 Stock Position in Merck & Co., Inc. $MRK

Adamsbrown Wealth Consultants LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 3,395 shares of the company’s stock after purchasing an additional 309 shares during the period. Adamsbrown Wealth Consultants LLC’s holdings in Merck & Co., Inc. were worth $269,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. McLean Asset Management Corp raised its position in Merck & Co., Inc. by 3.7% during the 2nd quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after purchasing an additional 125 shares during the last quarter. Foundation Wealth Management LLC PA increased its stake in shares of Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock valued at $481,000 after buying an additional 127 shares during the period. Saiph Capital LLC raised its position in shares of Merck & Co., Inc. by 3.7% during the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after acquiring an additional 128 shares during the last quarter. N.E.W. Advisory Services LLC lifted its stake in shares of Merck & Co., Inc. by 2.6% in the first quarter. N.E.W. Advisory Services LLC now owns 5,197 shares of the company’s stock worth $466,000 after acquiring an additional 130 shares during the period. Finally, Tilson Financial Group Inc. boosted its holdings in Merck & Co., Inc. by 2.7% in the first quarter. Tilson Financial Group Inc. now owns 4,965 shares of the company’s stock valued at $446,000 after acquiring an additional 132 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on MRK shares. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a research report on Tuesday, May 20th. Finally, Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $107.44.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $82.87 on Monday. The stock has a market capitalization of $206.99 billion, a price-to-earnings ratio of 12.77, a PEG ratio of 0.85 and a beta of 0.37. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $119.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock’s 50 day moving average price is $82.93 and its two-hundred day moving average price is $82.75.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The company had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 49.92%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.